Announcements Trials
Browse Landscape

Phase

Phase 3 12Phase 2 7Phase 2/3 4Phase 1 3Phase NA 2Phase 4 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 1

Conditions

Fatigue 2Neoplasms 1Multiple Endocrine Neoplasia Type 1 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Interventional × Methylphenidate × Clear all
NCT02361125 2022-01-04

Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate

M.D. Anderson Cancer Center

Phase 1 Completed
31 enrolled

Fatigue

NCT01164956 2019-04-26

Methylphenidate for Cancer-Related Fatigue

Dana-Farber Cancer Institute

Phase 1 Terminated
3 enrolled 7 charts

Fatigue, Neoplasms

NCT01202734 2014-05-16

A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 1 Completed
10 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡